Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**2-(2-chloropyridin-4‑yl)-4‑methyl‑1H‑isoindole‑1,3(2H)‑dione** is a synthetic small molecule belonging to the phthalimide class of organic compounds[2]. It has been studied as an inhibitor of bacterial thymidylate synthase (TS), with evidence suggesting it binds specifically to bacterial TS and exhibits higher affinity for the bacterial enzyme compared to the human counterpart. This selectivity makes it a potential lead compound for antibacterial drug development targeting thymidylate synthase in pathogenic bacteria[5]. The compound is primarily referenced in research and structural biology contexts and does not have established pharmaceutical use or marketed formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(2-chloropyridin-4-yl)-4-methyl-1H-isoindole-1,3(2H)-dione.